Jci_page_head_homepage_01 Jci_page_head_homepage_02
Debanjan Chakroborty, Uttio Roy Chowdhury, Chandrani Sarkar, Rathindranath Baral, Partha Sarathi Dasgupta, Sujit Basu
Published in Volume 118, Issue 4
J Clin Invest. 2008; 118(4):1380–1389 doi:10.1172/JCI33125
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5
DA inhibited VEGFA-induced mobilization of EPCs from the BM through its D2 receptors.

(A and B) Respective isotype controls. (CJ) Flow cytometric determination of CEPC frequency after completion of DA treatment. rhVEGFA was injected i.p. into normal mice for 5 continuous days. Immediately following VEGFA administration, each mouse received i.p. injection of DA (50 mg/kg body weight) for 5 consecutive days beginning from day 1 of VEGFA administration. CEPC frequency on treatment day 5 after completion of the treatment is represented. (K) Absolute number of EPCs in various groups. Treatment with eticlopride, a DA D2 receptor antagonist, prior to DA treatment completely abrogated the inhibitory effect of DA. Figures are representative of 4 separate experiments for each group. *P < 0.05.